Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GNS and HLBZ - why doesn’t NWBO provide some sort of quick update on the lawsuits. This seems to be the hot topic at the moment.
The Company is currently working on preparations for applications for regulatory approval of DCVax®-L.
Prob smart to release on Sunday when market is closed to let audience digest prior to Monday opening bell
Anyone concerned that NWBO stock buys are no longer allowed to occur at Raymond James?
Thank you
What will happen with all those friendly warrants or financing warrants post tld? Is the stock capped at 1B shares in circulation? Makes me think the plan is for a buyout to occur otherwise how would aforementioned be possible to facilitate? Have heard no plan in regards to how it will be possible to put all of those shares in circulation.
You have to scroll all the way down to the button of the “Agenda” page on the nyas site
The May 4th press release notes “this presentation can be viewed virtually”. I would hope the company will issue a PR this morning to clear this up in addition to change in speaker.
Has nothing to do with a last minute cancelation. Every other presenters bio was updated last week as well except Linda’s.
Every single other profile on the website has a profile bio except for LInda’s. Kind of odd all things considered? I would certainty hope the NYAS site has proper controls, systems restrictions and firewalls to prevent that. Your response is not a proper response to my question and is not helpful. Thanks
Nonsensical and careless to assume otherwise. A bio is a foundation of credibility. Something you would want a person to have who is speaking on behalf of your company. It’s sloppy but this board is to delusional to realize it
Odd Linda’s profile was never even updated on the nyas site. Not last week or today. Embarrassing effort from the company imo
Session 10 - poster session - not defined or speaker assigned for this one hour time slot at EOD. Perhaps, this slot is for Linda?
Does anyone know what “Session 10: Poster Session” - (i.e. one hour time slot at the end of Tuesday)? No description is given on the nyas agenda for this one hour time slot at the end of the day?
On Tuesday, last hour of conference has a “poster session” on the agenda. Any idea what that slot of 1 hour of time is reserved for?
Also, did the title of LLs 11:10am presentation get updated?
SEC filing notes “funds will be used for the company’s ongoing business operations”
NWBO vs. FATE market cap. Such a joke
Lol, no clue! First time I ever tried calling him!
Yes, smith hit something on the nail in regards to what Les could comment on. I never asked about a brief tld piece and he definitely didn’t say it wouldn’t happen! Shared my info in hopes this would maybe help some here. I’ve spent way to much time reading this board and it helped me realize to hold my shares and stop wasting 4 hours a day reading this board and be patient for results. Makes sense it takes a couple months to go through a 14 year trial if you ask me! De-risking of investment has taken place in Europe and trial definitely hasn’t failed. Little downside for big upside.
It was a real call. I still can’t believe he answered!
11/9/2020 – 10:55AM CST: Notes from discussion w/ Les Goldman:
Below are my notes from discussion with Les Goldman this morning. I think this should clear up some questions around how they will PR the data and timelines.
1. He referred to Smith’s recent article and noted that it offered more information then he was at liberty to say at the moment.
2. Warrants could get pushed out further
3. Will publish results in a Journal vs. a PR (in the context of this question it was noted warrants could get pushed out further)
4. Made it clear warrants were pushed out further for purposes of stopping the short sellers from getting additional shares.
5. Noted the company is still "mostly" blinded and made it a point to note the company is currently unaware of the trial failing
6. Pointed out the EU endpoint updates on the clinical site and it appears the company was surprised the clinical sites were updated.
7. Company is in a quiet period. When asking if a PR would be expected in near future it didn’t seem like we should expect to hear anything soon. Noted they will not rush reporting results of a 14 year trial they worked extremely hard on. Also, noted they want to do things right and is what is best for investors.
8. No partnerships with big pharma will occur until the results are published. He noted they have not spent the last 14 years to sellout and wouldn’t be fair to retail investors. Noted they have received small offers in the past.
9. Statisticians are still working on the data
10. Noted SITC and SNO were just placeholders and there are more placeholders if you look further down the road.
Overall, this cleared up some key items for me that so many on this board seem to speculated about. I have provided all my notes from the call and don't have any additional information.
Yep. Agree. 100 million shares hitting the market with a value of $200 million (based on today’s $2 share price) is $200 million. We know this is a $5 billion company on good results. Share price will be higher and warrants should not have more then 10% influence. Everyone has known about the warrants for a long time.
Regarding flip side of warrants hitting market in November / December....keep in mind these holders have a lot of money and will want to see the stock price continue to go up higher at least until November 1st so they can unload at a high and leave retail investors holding the bag....
Hello - can someone explain what the next announcement / when the announcement will most likely occur from the company? Is it for sure they announce DL prior to releasing trial results rather than all at once? Thank you for the hell.
Why is northwest calling me nonstop for a vote for the annual shareholder meeting?
Great to see the stock trading a little; someone must have wanted a few shares!
424B3 - Link to filings:
http://www.tapimmune.com/investors/financial-filings/
Thank you for sharing your stock picks Rk; much appreciated. Looks like some interesting news today.
Enumeral Reports That Its Novel Class of Potentially Allosteric Anti-PD-1 Antibodies Can Elicit an Additive Effect on T Cell Activation in Ex Vivo Human Assays When Used in Combination with a Currently Marketed Anti-PD-1 Antibody
8:00 am ET November 18, 2015 (BusinessWire) Print
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced that its novel class of potentially allosteric anti-PD-1 antibodies, when used in combination with conventional anti-PD-1 antagonists, provides additional enhancement of T cell function. It is believed that currently marketed anti-PD-1 antibodies must disrupt PD-1 interaction with PD-L1, a tumor cell-expressed negative regulatory ligand that suppresses T cell activity following PD-1 engagement. Enumeral's antibodies block PD-L1-mediated immunosuppression, but do not disrupt PD-1 interaction with PD-L1.
Enumeral's researchers employed ex vivo methods to determine responsiveness of tumor infiltrating lymphocytes (TILs) derived from lung biopsies to various anti-PD-1 antibodies, measuring restoration of interferon gamma production, which is a key cytokine reflective of T cell activation. The Company's researchers found that approximately 50% of assayed biopsies harbored TILs responsive to a series of anti-PD-1 antibodies. When a conventional anti-PD-1 antibody was combined with Enumeral's antibody, interferon gamma levels were further increased above controls in a subset of the responsive samples. Additionally, Enumeral researchers have found that TILs isolated from lung tumor biopsies that display elevated TIM-3 expression levels have lower responsiveness to the effects of anti-PD-1 antibodies in ex vivo assays.
"We are excited by these findings, building on our earlier observations that our potentially allosteric class of anti-PD-1 antibodies may elicit elevated T cell activation above that which is possible with currently marketed anti-PD-1 antibodies. An additive effect may indicate that our antibodies drive a qualitatively different biology through the PD-1 signaling axis, leading to a greater extent of T cell activation," said Cokey Nguyen, Ph.D., Enumeral's Vice President of Research and Development.
"Our observations on the possible additive effects of currently marketed anti-PD-1 antibodies when used in combination with our antibodies further demonstrates the differentiated activity of our novel class of anti-PD-1 antibodies," continued Dr. Nguyen. "Moreover, we observed that TIM-3 expression may correlate to hypo-responsiveness to PD-1 blockade, suggesting that combining an anti-TIM-3 antibody with an anti-PD-1 antibody could represent a testable therapeutic path for treatment of lung cancer."
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral's researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.
Forward Looking Statements Disclosure
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. ("Enumeral") with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, Enumeral's stock price, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include, among others, the risks that (a) Enumeral's expectations regarding market acceptance of the Company's business in general and the Company's ability to penetrate the antibody discovery and development fields in particular, as well as the timing of such acceptance, (b) Enumeral's ability to attract and retain management with experience in biotechnology and antibody discovery and similar emerging technologies, (c) the scope, validity and enforceability of Enumeral's and third party intellectual property rights, (d) Enumeral's ability to raise capital when needed and on acceptable terms and conditions, (e) Enumeral's ability to comply with governmental regulation, (f) the intensity of competition, (g) changes in the political and regulatory environment and in business and fiscal conditions in the United States and overseas and (h) general economic conditions.
More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral's filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission's website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20151118005362r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005362/en/
Is this TPIV run up due in part to all the AVXL money funneling back in?
Nov 7th Conference / Presentation: I think it's interesting if AVXL results are significant (positive) the company is reporting on a Saturday vs. week day when market is open? Any thoughts / input in regards to other companies that have choosed to release significant results on a Saturday?
Woodford financing - could nwbo be misleading in PR regarding him buying at premium of $5.50. Saw interesting article regarding Gale financing with Lincoln park capita on only disclosing the shares purchased at premium and not the large blocks given for free. Thanks for any help
12M / shares equates to about $6M dollars so not worried. Thanks
NW Bio Presenting New DCVax-Direct Poster At "The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival" In New York City On Wednesday, September 16, 2015
Dr. Marnix Bosch to Discuss Factors Related to Patient Survival in Phase I Trial
BETHESDA, Md., Sept. 16, 2015 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Chief Technical Officer, Dr. Marnix Bosch, will present a new DCVax-Direct poster at the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015. The Conference is being held at the Sheraton New York Times Square Hotel from September 16th to 19th, 2015.
This first of its kind conference is a collaboration of four prestigious cancer organizations on both sides of the Atlantic, demonstrating the ever increasing attention towards immunotherapy. They include the American Association of Cancer Research (AACR), the European Association for Cancer Immunotherapy (CIMT), the Cancer Research Institute (CRI), and the European Academy of Tumor Immunology (EATI).
Dr. Bosch will discuss new and emerging information from the Phase I trial of DCVax-Direct in regard to ongoing patient survival and factors associated with such survival. The poster is entitled "Cytokine Production by Human Dendritic Cells When Administered Intratumorally Correlates with Clinical Outcome in Subjects with Advanced Cancers." This poster presentation will be presented in the 6:45 to 8:45 pm (EDT) Session A on Wednesday, September 16, 2015.
In addition to Dr. Bosch, other authors on the poster presentation include Dr. Vivek Subbiah and colleagues from MD Anderson Hospital and from UT Health in Houston, as well as several representatives from Cognate Bioservices.
Good luck everyone tomorrow. Let's hope this time / conference is different. Let's hope tomorrow we don't have endless speculation...because we know.
Dan - congrats on vvus
Wildcard could be partnering or buyout as well? (Despite LP stating wouldn't bring much to the table). Guessing they have more going on right now then they can handle. In addition to needing money.
Would trials ever get halted for purposes of buyout or partnerships etc? Anyone know of any similar situations?
Any thoughts on why institutional buying has been limited?
Time to man up. Your long contrarian style; you put in to much work on the front end to sit on the sidelines. You'll be quietly cheering with the rest of us who face capital gains problems at YE